Tenshang Joh

1.3k total citations
32 papers, 1.0k citations indexed

About

Tenshang Joh is a scholar working on Oncology, Immunology and Surgery. According to data from OpenAlex, Tenshang Joh has authored 32 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 13 papers in Immunology and 10 papers in Surgery. Recurrent topics in Tenshang Joh's work include Monoclonal and Polyclonal Antibodies Research (8 papers), Lipoproteins and Cardiovascular Health (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Tenshang Joh is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), Lipoproteins and Cardiovascular Health (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Tenshang Joh collaborates with scholars based in United States, Japan and Netherlands. Tenshang Joh's co-authors include Matthew D. Linnik, Donald G. Albert, Jenny Heathcote, Jay H. Hoofnagle, Myron J. Tong, William M. Lee, Paul J. Pockros, K. Rajender Reddy, Vibeke Strand and Daniel J. Wallace and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

Tenshang Joh

30 papers receiving 977 citations

Peers

Countries citing papers authored by Tenshang Joh

Since Specialization

Citations

This map shows the geographic impact of Tenshang Joh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tenshang Joh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tenshang Joh more than expected).

Fields of papers citing papers by Tenshang Joh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tenshang Joh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tenshang Joh. The network helps show where Tenshang Joh may publish in the future.

Co-authorship network of co-authors of Tenshang Joh

This figure shows the co-authorship network connecting the top 25 collaborators of Tenshang Joh. A scholar is included among the top collaborators of Tenshang Joh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tenshang Joh. Tenshang Joh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Meta-analysis comparing the incidence of serious adverse events, overall survival, and progression-free survival in patients with pancreatic adenocarcinoma harboring unresectable tumors treated with modified FOLFIRINOX or FOLFIRINOX regimen. 2024 ·Journal of Clinical Oncology ·Vuong Trieu, Sanjive Qazi, Seymour Fein, (unknown), Tenshang Joh	1
2	Model-Based Characterization of the Pharmacokinetics, Target Engagement Biomarkers, and Immunomodulatory Activity of PF-06342674, a Humanized mAb Against IL-7 Receptor-α, in Adults with Type 1 Diabetes 2020 ·The AAPS Journal ·Jason H. Williams, Chandrasekhar Udata, Bishu Ganguly, Samantha Bucktrout, Tenshang Joh, (unknown), Gilbert Y. Wong, Matteo Levisetti, Pamela D. Garzone, Meng Xu	10
3	Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma 2019 ·Investigational New Drugs ·Marcus Smith Noel, Eileen M. O’Reilly, Brian M. Wolpin, David P. Ryan, Andrea J. Bullock, Carolyn D. Britten, David C. Linehan, Brian A. Belt, (unknown), Bishu Ganguly, Donghua Yin, Tenshang Joh, Ira Jacobs, Carrie Turich Taylor, Maeve A. Lowery	145
4	Immunomodulatory activity of humanized anti–IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes 2019 ·JCI Insight ·Kevan C. Herold, Samantha Bucktrout, (unknown), Bruce W. Bode, Stephen E. Gitelman, Peter A. Gottlieb, Jing W. Hughes, Tenshang Joh, Janet B. McGill, Jeremy Pettus, Shobha Potluri, Desmond Schatz, (unknown), Chandrasekhar Udata, Gilbert Y. Wong, Matteo Levisetti, Bishu Ganguly, Pamela D. Garzone	27
5	Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial 2018 ·Endocrine ·Barry Gumbiner, Brooke Esteves, (unknown), Tenshang Joh, Pamela D. Garzone, Alison Forgie, Chandrasekhar Udata	13
6	Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high‐dose statin 2017 ·Cardiovascular Therapeutics ·Sergio Fazio, David Robertson, Tenshang Joh, Hong Wan, (unknown), (unknown), Charles M. Baum, Pamela D. Garzone, Barry Gumbiner	15
7	The effects of single‐ and multiple‐dose administration of bococizumab (RN316/PF‐04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies 2017 ·Cardiovascular Therapeutics ·Barry Gumbiner, Tenshang Joh, Liang Hong, Hong Wan, Matteo Levisetti, (unknown), David L. Shelton, (unknown), (unknown), Jaume Pons, Charles M. Baum, Pamela D. Garzone	14
8	Safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from a phase I dose-escalation study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) in combination with utomilumab, a 4-1BB agonistic mAb 2017 ·Annals of Oncology ·Omid Hamid, Willeke Ros, John A. Thompson, Siwen Hu‐Lieskovan, Fredericus Eskens, Adi Diab, Toshihiko Doi, Jeffrey S. Wasser, (unknown), Naiyer A. Rizvi, Eric Angevin, Alberto Chiappori, Patrick A. Ott, Bishu Ganguly, Catherine Fleener, (unknown), Kuo‐Wei Liao, Tenshang Joh, Jeffrey Chou, (unknown)	2
9	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects 2017 ·Clinical Therapeutics ·Hong Wan, Barry Gumbiner, Tenshang Joh, (unknown), Chandrasekhar Udata, (unknown), Pamela D. Garzone	10
10	A first-in-human (FIH) study of PF-04518600 (PF-8600) OX40 agonist in adult patients (pts) with select advanced malignancies 2016 ·Annals of Oncology ·Adi Diab, Anthony B. El-Khoueiry, Ferry A.L.M. Eskens, Willeke Ros, John A. Thompson, Cyril Konto, (unknown), Tenshang Joh, Kuo‐Wei Liao, Bishu Ganguly, Omid Hamid	12
11	First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results. 2016 ·Journal of Clinical Oncology ·Omid Hamid, John A. Thompson, Adi Diab, Willeke Ros, Ferry A.L.M. Eskens, (unknown), Cyril Konto, Hua Long, (unknown), Bishu Ganguly, Catherine Fleener, Susan Pleasic‐Williams, Pamela D. Garzone, Premal H. Patel, Tenshang Joh, Dimitry S.A. Nuyten, Anthony B. El-Khoueiry	22
12	A phase 1 study of PF-06647020, an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients with advanced solid tumors including platinum resistant ovarian cancer (OVCA) 2016 ·Annals of Oncology ·Jasgit C. Sachdev, Michael L. Maitland, Monica Sharma, Víctor Moreno, Valentina Boni, Shivaani Kummar, (unknown), Dawei Xuan, Tenshang Joh, Eric L. Powell, Amy Jackson-Fisher, Marc Damelin, Xiaohua Xin, Anthony W. Tolcher, Emiliano Calvo	15
13	EFFECTS OF RN316 (PF-04950615), A HUMANIZED IGG2ΔA MONOCLONAL ANTIBODY BINDING PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9, ON LIPOPROTEIN PARTICLES IN HYPERCHOLESTEROLEMIC SUBJECTS 2013 ·Journal of the American College of Cardiology ·Hong Wan, Barry Gumbiner, Tenshang Joh, Chandrasekhar Udata, (unknown), Pamela D. Garzone	4
14	Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial 2008 ·Arthritis & Rheumatism ·Mario H. Cardiel, James A. Tumlin, Richard Furie, Daniel J. Wallace, Tenshang Joh, Matthew D. Linnik	107
15	Relationship between anti–double‐stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus 2005 ·Arthritis & Rheumatism ·Matthew D. Linnik, (unknown), (unknown), Vibeke Strand, (unknown), Tenshang Joh	162
16	Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. 2004 ·PubMed ·John Tesser, Roy Fleischmann, Robin K. Dore, (unknown), Alan M. Solinger, Tenshang Joh, (unknown), Joy Schechtman	29
17	Safety Of Combination Therapy With Anakinra And Etanercept In Patients With Rheumatoid Arthritis. 2001 ·Arthritis & Rheumatism ·(unknown), (unknown), (unknown), Mark C. Genovese, Shira Cohen, D E Furst, M. Weinblatt, Richard W. Martin, Larry W. Moreland, F Kazazi, Tenshang Joh, Richard Newmark, (unknown)	23
18	Efficacy of interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhotics, fibrotics, or nonfibrotics 1999 ·Hepatology ·Gregory T. Everson, Donald M. Jensen, John R. Craig, Dirk J. van Leeuwen, Vincent G. Bain, Murray N. Ehrinpreis, Donald G. Albert, Tenshang Joh, Karsten Witt	49
19	Multiple parapapillary choledochoduodenal fistulas with ampullary carcinoma. 1999 ·PubMed ·(unknown), (unknown), Takayuki Ando, Hidehiro Tokunaga, T Miyamoto, (unknown), (unknown), (unknown), Tenshang Joh, (unknown)	3
20	The value of CT in the preoperative evaluation of the rectal carcinoma. 1984 ·Nihon Daicho Komonbyo Gakkai Zasshi ·(unknown), (unknown), (unknown), Shigeo Ohki, Tenshang Joh, (unknown), (unknown)	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact